Aquatic Capital Management Buys Stake in Halozyme Therapeutics

Biopharmaceutical company sees increased institutional investment

Mar. 16, 2026 at 7:23am

Got story updates? Submit your updates here. ›

Aquatic Capital Management LLC has acquired 89,651 shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biopharmaceutical company headquartered in San Diego, California. The purchase, valued at approximately $6.575 million, represents about 0.08% ownership of Halozyme Therapeutics.

Why it matters

The investment by Aquatic Capital Management reflects growing institutional interest in Halozyme Therapeutics, which specializes in drug delivery technologies. As a biopharmaceutical company, Halozyme's performance and growth potential are closely watched by the investment community.

The details

According to a recent 13F filing with the SEC, Aquatic Capital Management purchased the 89,651 shares of Halozyme Therapeutics during the third quarter. The purchase makes Aquatic Capital Management a new investor in the company, which is known for its ENHANZE® technology platform that enables subcutaneous administration of biologic therapies.

  • Aquatic Capital Management purchased the Halozyme Therapeutics shares during the third quarter of the year.

The players

Aquatic Capital Management LLC

An investment management firm that has acquired a stake in Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California that specializes in drug delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

The investment by Aquatic Capital Management in Halozyme Therapeutics reflects the growing interest in the company's drug delivery platform and its potential to improve patient access and convenience for biologic therapies.